Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895877 | 0.81 | ADRB2 (0.36) | KDM4EALDH1A1HPGDMAPTNPSR1 | |
| SCHEMBL7498463 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL5422350 | 0.72 | ALDH1A1 (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL7568263 | 0.71 | ALDH1A1 (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5426507 | 0.69 | ALDH1A1 (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5425492 | 0.69 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5428842 | 0.69 | ALDH1A1 (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL4964335 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1290318 | 0.68 | KDM4E (0.41) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL5424777 | 0.68 | KDM4E (0.42) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | IL4I1, TLR5, IFNG | KDM4E 2031/4885ALDH1A1 1427/4885GLA 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.